Clinical Trials Logo

Osteosarcoma clinical trials

View clinical trials related to Osteosarcoma.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT04861948 Terminated - Solid Tumors Clinical Trials

IBI188 Combination Therapy in Solid Tumors

Start date: May 25, 2021
Phase: Phase 1
Study type: Interventional

A Phase Ib study aim to evaluate the efficacy, safety, and tolerability of IBI188 combination therapy in subjects with advanced malignancies

NCT ID: NCT04365660 Terminated - Osteosarcoma Clinical Trials

18F-FTC-146 PET/CT in Newly-Diagnosed Osteosarcoma

Start date: January 28, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this research is to evaluate the study drug, 18F FTC-146, as a positron emission tomography (PET) / computed tomography (CT) radiotracer imaging agent to evaluate tumor status in patients newly diagnosed with osteosarcoma ("bone cancer").

NCT ID: NCT03860207 Terminated - Neuroblastoma Clinical Trials

Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers

Start date: February 22, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to test the safety of a study drug called humanized 3F8 bispecific antibody (Hu3F8-BsAb).

NCT ID: NCT03468075 Terminated - Sarcoma Clinical Trials

Gemcitabine Plus Ascorbate for Sarcoma in Adults

Start date: July 11, 2018
Phase: Phase 2
Study type: Interventional

This study will enroll patients who have a diagnosis of locally advanced, unresectable or metastatic soft tissue or bone sarcoma (except gastrointestinal stromal tumors and Kaposi's sarcoma) from any site.

NCT ID: NCT03458728 Terminated - Neuroblastoma Clinical Trials

Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients

Start date: April 30, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This study is designed to investigate whether the use of copanlisib is safe, feasible and beneficial to pediatric patients with solid solid tumors or lymphoma that are recurrent or refractory to standard therapy.

NCT ID: NCT03422679 Terminated - Breast Cancer Clinical Trials

Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies

Start date: December 5, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase I/II, non randomized, open-label, dose escalation study to investigate the safety, tolerability and preliminary efficacy of CB-103.

NCT ID: NCT03139318 Terminated - Radiation Toxicity Clinical Trials

Phase I Clinical Trial of GRID Therapy in Pediatric Osteosarcoma of the Extremity

Start date: July 25, 2017
Phase: N/A
Study type: Interventional

The primary objective of this study is to evaluate the toxicity profile of GRID therapy using dose levels of 10Gy, 15 Gy and 20Gy in pediatric osteosarcoma of the extremity.

NCT ID: NCT03013127 Terminated - Osteosarcoma Clinical Trials

A Study of Pembrolizumab in Patients With Relapsed Or Metastatic Osteosarcoma Not Eligible for Curative Surgery

PROMO
Start date: May 30, 2017
Phase: Phase 2
Study type: Interventional

This is a phase II, single arm, open-label, interventional trial of pembrolizumab (MK-3475) in patients with osteosarcoma who have experienced disease relapse or progression after at least one line of systemic treatment, and who are not eligible for curative surgery.

NCT ID: NCT02718482 Terminated - OSTEOSARCOMA Clinical Trials

Phase II Trial for the Treatment of Relapsed Osteosarcoma

OsteoREC2015
Start date: April 6, 2016
Phase: Phase 2
Study type: Interventional

Phase II randomized study for the comparison of the Gemcitabine plus Docetaxel and the Ifosfamide treatment of patients with relapsed osteosarcoma

NCT ID: NCT02581384 Terminated - Sarcoma Clinical Trials

Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors

Start date: January 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This research study is studying stereotactic body radiotherapy (SBRT) as a possible treatment for lung relapse of Ewing sarcoma, rhabdomyosarcoma, osteosarcoma, non-rhabdomyosarcoma soft tissue sarcoma, Wilms tumor or other primary renal tumor (including clear cell and rhabdoid). SBRT is a form of targeted radiotherapy that can treat very small tumors using a few large doses.